Rapport Therapeutics (RAPP) Stock Price, News & Analysis

Company Overview

Rapport Therapeutics is a clinical-stage biopharmaceutical company focused on developing medicines for disorders of the central nervous system. The company’s research centers on receptor-associated proteins, which help regulate neurotransmitter receptors and may provide opportunities to develop more selective therapies than those that target receptors broadly.

Rapport’s lead development program, RAP-219, is an orally administered investigational therapy designed to modulate AMPA receptors through their associated proteins. The program is being evaluated for focal epilepsy and may have potential applications in other neurological and psychiatric disorders. As an investigational medicine, RAP-219 has not been approved for commercial use.

Rapport was established in 2018 with backing from PureTech Health and became a publicly traded company on the Nasdaq in 2024. The company is headquartered in Boston, Massachusetts, and its research and development activities are directed toward addressing significant unmet needs in neurological disease. Rapport Therapeutics is led by President and Chief Executive Officer Don Nicholson.

Key Stats

• Today's Range: $40.29 to $43.00
• 50-Day Range: $39.93 to $52.50
• 52-Week Range: $23.75 to $52.93
• Volume: 998,056 shs
• Average Volume: 285,579 shs
• Market Capitalization: $1.94 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $64.29
• Consensus Rating: Buy

Rapport Therapeutics Stock Analysis - MarketRank™

Rapport Therapeutics scored higher than 48% of companies evaluated by MarketBeat, and ranked 482nd out of 905 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.5 / 5
• Analyst Rating: Buy

Consensus Rating

Rapport Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 strong buy ratings, 10 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Rapport Therapeutics has a consensus price target of $64.29, representing about 58.9% upside from its current price of $40.45.

Amount of Analyst Coverage

Rapport Therapeutics has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Rapport Therapeutics are expected to decrease in the coming year, from ($4.09) to ($4.92) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Rapport Therapeutics is -13.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Rapport Therapeutics is -13.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Rapport Therapeutics has a P/B Ratio of 3.98. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

5.32% of the float of Rapport Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Rapport Therapeutics has a short interest ratio ("days to cover") of 8.23.

Change versus previous month

Short interest in Rapport Therapeutics has recently increased by 0.36%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Rapport Therapeutics does not currently pay a dividend.

Dividend Growth

Rapport Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 1.6 / 5
• News Sentiment: 0.62

News Sentiment

Rapport Therapeutics has a news sentiment score of 0.62. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Rapport Therapeutics this week, compared to 4 articles on an average week.

MarketBeat Follows

Only 1 people have added Rapport Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

Company Ownership

• Score: 1.2 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Rapport Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,858,615.00 in company stock.

Percentage Held by Insiders

12.48% of the stock of Rapport Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Rapport Therapeutics has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 8/05/2026
• Today: 9/19/2026
• Status update: 9/22/2026
• TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit: 9/23/2026
• Next Earnings (Estimated): 11/05/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:RAPP
• Previous Symbol: NASDAQ:RAPP
• CIK: 2012593
• Web: www.rapportrx.com
• Phone: (857) 321-8020
• Fax: N/A
• Employees: 84
• Year Founded: 2022

Price Target and Rating

• Average Price Target for Rapport Therapeutics: $64.29
• High Price Target: $80.00
• Low Price Target: $46.00
• Potential Upside/Downside: +58.9%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 13 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.04)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$111.48 million
• Net Margins: N/A
• Pretax Margin: -685.80%
• Return on Equity: -29.02%
• Return on Assets: -27.37%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 15.72
• Quick Ratio: 15.72

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $10.17 per share
• Price / Book: 3.98

Miscellaneous

• Outstanding Shares: 47,980,000
• Free Float: 41,990,000
• Market Cap: $1.94 billion
• Optionable: N/A
• Beta: 1.02